Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain.

Category Primary study
JournalPain research & management : the journal of the Canadian Pain Society = journal de la société canadienne pour le traitement de la douleur
Year 2010
OBJECTIVE: The present randomized, double-blinded, crossover study compared the efficacy and safety of a seven-day buprenorphine transdermal system (BTDS) and placebo in patients with low back pain of moderate or greater seventy for at least six weeks. METHODS: Prestudy analgesics were discontinued the evening before random assignment to 5 µg/h BTDS or placebo, with acetaminophen 300 mg/codeme 30 mg, one to two tablets every 4 h to 6 h as needed, for rescue analgesia. The dose was titrated to effect weekly, if tolerated, to 10 µg/h and 20 µg/h BTDS. Each treatment phase was four weeks. RESULTS: Fifty-three patients (28 men, 25 women, mean [± SD] age 54-5 ± 12.7 years) were evaluable for efficacy (completed two weeks or more in each phase). Baseline pain was 62.1 ± 15.5 mm (100 mm visual analogue scale) and 2.5 ± 0.6 (five-point ordinal scale). BTDS resulted in lower mean daily pain scores than in the placebo group (37.6 ± 20.7 mm versus 43.6 ± 21 2 mm on a visual analogue scale, P = 0.0487; and 1.7 ± 0.6 versus 2.0 ± 0.7 on the ordinal scale, P = 0 0358) Most patients titrated to the highest dose of BTDS (59% 20 µg/h, 31% 10 µg/h and 10% 5 µg/h) There were improvements from baseline in pain and disability (Pain Disability Index), Pain and Sleep (visual analogue scale), Quebec Back Pain Disability Scale and Short-Form 36 Health Survey scores for both BTDS and placebo groups, without significant differences between treatments. While there were more opioid-related side effects with BTDS treatment than with placebo, there were no serious adverse events. A total of 82% of patients chose to continue BTDS in a long-term open-label evaluation, in whom improvements in pain intensity, functionality and quality of life were sustained for up to six months without analgesic tolerance. CONCLUSION: BTDS (5 µg/h to 20 µg/h) represents a new treatment option for initial opioid therapy in patients with chronic low back pain. (PsycInfo Database Record (c) 2025 APA, all rights reserved)
Epistemonikos ID: 1e73f4d6318a7942225ac2680c3d283f77c279c8
First added on: Oct 27, 2014